Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us

PBD Biotech gains funding to fuel overseas expansion

To meet the growing international demand for its rapid, sensitive test for mycobacterial disease, PBD Biotech is to establish a Canadian subsidiary in Saskatoon to support its first overseas commercial activity.
  • June 27, 2018
  • Company
  • international, investment
New Anglia LEP CEO Chris Starkie and PBD Biotech CEO Berwyn Clarke
New Anglia LEP CEO Chris Starkie and PBD Biotech CEO Berwyn Clarke

Detecting TB in livestock and wild animals is a challenge worldwide.

The start-up’s international expansion has been made possible, just 12 months on from its launch, by new funding from New Anglia Capital – announced at the Royal Norfolk Show.

Dr Berwyn Clarke, CEO of PBD Biotech, said: “This investment from New Anglia Capital, and other investors, has enabled us to take the next-step in getting the Actiphage® technology into international markets.

“It has accelerated the company’s timeline, meaning we’re about six months ahead of where we were expecting to be. We now have a number of commercial opportunities all over the world that are ready to go. For an early-stage company this is an exciting position to be in.”

New Anglia Capital is a co-investment fund, managed by New Anglia Local Enterprise Partnership (LEP) in partnership with Anglia Capital Group, that brings angel investors together to kick-start new products and innovative ideas, as well as supporting existing high growth companies.

Commenting on the £125k investment in PBD Biotech, New Anglia LEP CEO Chris Starkie said: “Seed funding of this kind is vital for businesses to take innovative new ideas and turn them into something tangible – with job creation and economic growth the result.

“PBD Biotech is doing just that, and doing it within an industry sector that plays a key role in driving our economy forward.”

Earlier this month, PBD Biotech visited Canada as part of an innovation mission supported by Innovate UK.

It was through the 2017 Saskatoon Regional Economic Development Authority’s (SREDA) Agriculture Technology Harvest Program that PBD Biotech first showcased its novel technology to progressive organisations in the region. The relationships formed have been so fruitful that the company has chosen the province for its base.

Alex Fallon, SREDA President and CEO, explained: “Saskatchewan has long been a leader in animal and food health and is always looking to implement new processes and technology that benefit farmers and customers. PBD Biotech’s expansion to Saskatchewan will position the company for success in the Canadian market and ensure we’re at the forefront of utilising innovative products in this key sector.”

The proven Actiphage technology has the potential to become a significant tool in the detection and control of tuberculosis, Johne’s Disease and other mycobacterial diseases in animals as well as humans.

PBD Biotech’s highly sensitive and specific assay detects live bacteria in the blood or milk of cattle, sheep, elk and other exotic species in just six hours. It offers zoology and exotic species experts, veterinary surgeons, food manufacturers and farmers the opportunity for early and accurate detection of live bacteria, facilitating improved containment and control of diseases as well as food safety.

In May 2018, the UK Government accepted PBD Biotech’s phage-based technology for exceptional private use on TB-stricken cattle herds in England and international discussions are underway to market Actiphage in multiple regions including the USA, France, Dubai, Argentina, Brazil and Canada.

PBD Biotech was founded to develop and commercialise the Actiphage test from a technology originally used to detect TB in humans and adapted by Drs Cath Rees and Ben Swift at the University of Nottingham. It was set-up with funding from Nottingham University and New Anglia LEP’s co-investment fund.

The new funding will support international commercialisation of the diagnostic products and further field-based validation.

Share:

Related posts

Loading...
Tom Kellner

PBD Biotech expands its North American operations

January 27, 2022
PBD Biotech is expanding its North American team. Tuberculosis (TB) and Johne’s Disease expert Tom Kellner has been appointed as Director of Operations in North America, to advise on regulatory affairs and provide technical and customer support.
Tom Kellner

PBD Biotech expands its North American operations

January 27, 2022
PBD Biotech is expanding its North American team. Tuberculosis (TB) and Johne’s Disease expert Tom Kellner has been appointed as...
Actiphage

PBD Biotech gains attention of East of England Investment Catalyst among other investors

October 7, 2019
TB in humans and animals is a huge global problem as there is a lack of rapid, accurate ways to detect the disease at an early stage. PBD Biotech has developed Actiphage®, a new sensitive test that can detect the...
Actiphage

PBD Biotech gains attention of East of England Investment Catalyst among other investors

October 7, 2019
TB in humans and animals is a huge global problem as there is a lack of rapid, accurate ways to...
Blood test

International demand for first sensitive test for mycobacteria in blood or milk

August 15, 2018
Bovine TB is one of a group of diseases caused by mycobacteria that has devastated the agricultural industry worldwide. Now UK agri-tech start-up PBD Biotech, developers of the first rapid test for live mycobacteria, has secured £400,000 in its first...
Blood test

International demand for first sensitive test for mycobacteria in blood or milk

August 15, 2018
Bovine TB is one of a group of diseases caused by mycobacteria that has devastated the agricultural industry worldwide. Now...
Dr Berwyn Clarke at REAP

‘Angel investors bring more than money’ – Interview with PBD Biotech CEO

August 7, 2018
Following PBD Biotech’s successful seed funding round, CEO Dr Berwyn Clarke spoke to Growth Business, the leading media portal for entrepreneurs, about the start-up’s strategic approach to securing the right investment for phage-based technology.
Dr Berwyn Clarke at REAP

‘Angel investors bring more than money’ – Interview with PBD Biotech CEO

August 7, 2018
Following PBD Biotech’s successful seed funding round, CEO Dr Berwyn Clarke spoke to Growth Business, the leading media portal for...
1 2 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB

Read More
PBD Biotech

Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies

Read More
PBD Biotech

Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease

Read More